These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 5082266)

  • 1. [Analysis of iomeglamic acid (Falignost)].
    Pfeifer S; Schäffner J; Bornschein I
    Pharmazie; 1972 Jun; 27(6):396-403. PubMed ID: 5082266
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biotransformation of iomeglamic acid (Falignost)].
    Bornschein I; Borchert HH; Pfeifer S
    Pharmazie; 1974; 29(10-11):730-1. PubMed ID: 4438422
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biotransformation of iomeglamic acid (Falignost)].
    Bornschein I; Schäffner J; Pfeifer S
    Pharmazie; 1975 Mar; 30(3):196. PubMed ID: 1153481
    [No Abstract]   [Full Text] [Related]  

  • 4. [Biotransformation of iomeglamic acid (Falignost)].
    Pfeifer S; Schäffner J; Bornschein I
    Pharmazie; 1972 Sep; 27(9):616-7. PubMed ID: 5086367
    [No Abstract]   [Full Text] [Related]  

  • 5. [Radiopaque contrast media. XXXVI - Iopronic acid: proposed analytical monograph].
    Felder E; Zingales MF; Tiepolo U
    Farmaco Prat; 1976 Aug; 31(8):383-95. PubMed ID: 955052
    [No Abstract]   [Full Text] [Related]  

  • 6. Radiopaque contrast media. XXV. Physicochemical properties of iodoxamic acid, a new intravenous cholecystographic agent.
    Felder E; Pitré D; Grandi M
    Farmaco Sci; 1973 Nov; 28(11):925-36. PubMed ID: 4762845
    [No Abstract]   [Full Text] [Related]  

  • 7. [Results and conclusions from metabolic studies of I 131 -falignost].
    Barke R; Hieckel HG
    Radiol Diagn (Berl); 1972; 13(6):805-15. PubMed ID: 4657544
    [No Abstract]   [Full Text] [Related]  

  • 8. [Improvement of the solubility of problem drugs. 1. Production of iomeglamic acid fused and solidified products].
    Fahr F; Kala H; Pollandt P; Wenzel U; Masthoff F
    Pharmazie; 1985 Jun; 40(6):408-9. PubMed ID: 4034650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The improvement of solubility behavior of problem drugs. 2. Solubility behavior of slow dissolving products of iomeglamic acid and succinic acid].
    Fahr F; Kala H; Scharrenweber F
    Pharmazie; 1985 Jan; 40(1):60-1. PubMed ID: 3991791
    [No Abstract]   [Full Text] [Related]  

  • 10. [Biotransformation of iomeglamic acid (Falignost)].
    Pfeifer S; Schäffner J; Bornschein I; Kraft R
    Pharmazie; 1972 Jun; 27(6):403-10. PubMed ID: 5082267
    [No Abstract]   [Full Text] [Related]  

  • 11. [Improvement of the solubility of problem drugs. 17. Processing of iomeglamic acid/methylcellulose coprecipitates in tablets].
    Fahr F; Kala H; Hückel T; Fries G
    Pharmazie; 1988 Mar; 43(3):216. PubMed ID: 3380870
    [No Abstract]   [Full Text] [Related]  

  • 12. [Improvement of the solubility of problem drugs. 18. Iomeglamic acid-PVA effervescent powder].
    Fahr F; Kala H; Fries G; Helbig G
    Pharmazie; 1988 Mar; 43(3):217. PubMed ID: 3380871
    [No Abstract]   [Full Text] [Related]  

  • 13. [Improvement of the solubility behavior of problem drugs. 20. The effect of pharmaceutical excipients on the wetability of iomeglamic acid].
    Fahr F; Zessin G; Kala H; Fries G
    Pharmazie; 1989 Aug; 44(8):576-7. PubMed ID: 2594830
    [No Abstract]   [Full Text] [Related]  

  • 14. [Improvement of the solubility behavior of problem drugs. 9. In vitro absorption studies using melting solidification products of iomeglamic acid].
    Fahr F; Neubert R; Fürst W; Kala H; Masthoff F
    Pharmazie; 1986 Dec; 41(12):855-6. PubMed ID: 3575388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Improvement of the solubility of problem drugs. 15. X-ray diffraction of iomeglamic acid-methylcellulose (MH 300)-PEG 6000-coprecipitate].
    Fahr F; Kala H; Pollandt P; Hückel T; Fries G
    Pharmazie; 1987 Aug; 42(8):554. PubMed ID: 3432342
    [No Abstract]   [Full Text] [Related]  

  • 16. [Improvement of the dissolution behavior of problem drugs. 11. DTA iomeglamic-PVP 25 copreciptates].
    Fahr F; Kala H; Masthoff F; Fries G
    Pharmazie; 1986 Jul; 41(7):517. PubMed ID: 3774866
    [No Abstract]   [Full Text] [Related]  

  • 17. [Improvement of the dissolution behavior of problem drugs. 3. X-ray diffraction measurement of iomeglamic acid/succinic acid solid dispersions].
    Fahr F; Kala H; Pollandt P
    Pharmazie; 1985 Feb; 40(2):127-8. PubMed ID: 4001148
    [No Abstract]   [Full Text] [Related]  

  • 18. [Improvement of the dissolution behavior of problem drugs. 4. Differential thermal analysis of iomeglamic acid-succinic acid embedding].
    Fahr F; Kala H; Masthoff F
    Pharmazie; 1985 Apr; 40(4):270-1. PubMed ID: 4011664
    [No Abstract]   [Full Text] [Related]  

  • 19. [The improvement of solubility behavior of problem drugs. 7. Iomeglamic acid-mannitol-melting viscosity products].
    Fahr F; Kala H; Pollandt P; Zessin G
    Pharmazie; 1985 Oct; 40(10):733-4. PubMed ID: 3936061
    [No Abstract]   [Full Text] [Related]  

  • 20. [Improvement of the solubility of problem drugs. 15. Alteration of iomeglamic acid-methylcellulose (MH 300)-PEG 6000 coprecipitates].
    Fahr F; Kala H; Pollandt P; Fries G; Hückel T
    Pharmazie; 1987 Aug; 42(8):552-3. PubMed ID: 3432340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.